ArticleInternational journal of chronic obstructive pulmonary disease2025
Associations of Serum Legumain with Severity and Prognosis Among Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A number of studies have demonstrated that legumain is engaged in the pulmonary diseases. Nevertheless, the role of legumain is indistinct in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The aim is to identify the correlation of serum legumain with AECOPD patients through a prospective cohort study. Methods: All 202 patients with AECOPD were enrolled. Fasting venous blood was collected. Serum legumain was detected by ELISA. Results: On admission, serum legumain concentration was gradually elevated in line with AECOPD severity scores. Additionally, serum legumain was closely associated with clinical characteristics. Linear regression analysis confirmed the positive relationships of serum legumain with COPD severity scores. Moreover, the poor prognoses were tracked in patients of AECOPD. Serum higher legumain at admission increased the risks of death and acute exacerbation during hospitalization. Conclusion: Serum legumain at admission was positively correlated with the severity and adverse prognosis in AECOPD patients, indicating that legumain plays a vital role in the initiation and development of AECOPD. As a result, serum legumain can become a biomarker in the disease assessment and prognosis prediction for AECOPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.